PLoS ONE, 2014 BackgroundPalonosetron is a potent second generation 5- hydroxytryptamine-3 selective antagonist which can be administered by either intravenous (IV) or oral routes, but subcutaneous (SC) administration of palonosetron has never been studied, even though
Belen Sadaba +10 more
doaj +2 more sources
Stability indicating Rp-UPLC method development and validation for the simultaneous estimation of fosnetupitant and palonosetron in bulk and injection dosage form [PDF]
Brazilian Journal of Pharmaceutical Sciences, 2022 A stability indicating UPLC method has been developed and validated for the simultaneous determination of fosnetupitant and palonosetron in bulk and in injection dosage form.
Poojari Venkatesh +5 more
doaj +3 more sources
The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting [PDF]
Cancer Management and Research, 2015 Swetha Rao Palli,1 Michael Grabner,1 Ralph A Quimbo,1 Hope S Rugo2 1HealthCore, Wilmington, DE, 2University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA Purpose: To determine the incidence of ...
Palli SR, Grabner M, Quimbo RA, Rugo HS
doaj +4 more sources
Evaluation of the ability of continuous palonosetron infusion, using a patient-controlled analgesia device, to reduce postoperative nausea and vomiting [PDF]
Korean Journal of Anesthesiology, 2014 BackgroundThe efficacy of palonosetron in preventing postoperative nausea and vomiting (PONV), as well as chemotherapy-induced nausea and vomiting, has already been demonstrated in multiple clinical studies.
Ji Won Kang, Soo Kyoung Park
doaj +3 more sources
Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study [PDF]
BMC Health Services Research, 2012 Background 1st generation 5-hydroxytryptamine receptor antagonists (5-HT3 RAs), and palonosetron, a 2nd generation 5-HT3 RA, are indicated for the prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) associated with moderately (MEC) and ...
Lin Swu-Jane +4 more
doaj +2 more sources
NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK [PDF]
, 2017 Background: The objective was to evaluate the cost-effectiveness of NEPA, an oral fixed combination netupitant (NETU, 300 mg) and palonosetron (PA, 0.5 mg) compared with aprepitant and palonosetron (APPA) or palonosetron (PA) alone, to prevent ...
Bourhis, Francois +7 more
core +4 more sources
Comparison of efficacy and safety between palonosetron and ondansetron to prevent postoperative nausea and vomiting in patients undergoing laparoscopic surgery: a systematic review and meta-analysis [PDF]
Journal of Minimally Invasive SurgeryPurpose: Postoperative nausea and vomiting (PONV) is a prevalent and distressing complication, especially in laparoscopic surgeries. This review compares the efficacy and safety of palonosetron and ondansetron in preventing PONV after laparoscopic ...
Jitendra Kumar +11 more
doaj +2 more sources
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy [PDF]
Cancer Management and Research, 2009 Rudolph M NavariIndiana University School of Medicine South Bend, South Bend, IN USAAbstract: Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life.
Rudolph M Navari
doaj +3 more sources
Effect of intravenous palonosetron on hypotension induced by spinal anesthesia for cesarean section: A randomized controlled trial. [PDF]
PLoS ONEBackgroundThe aim of this study was to evaluate the impact of intravenous palonosetron compared to ondansetron on hypotension induced by spinal anesthesia in women undergoing cesarean section.MethodsFifty-four women scheduled for elective cesarean ...
Min Kyoung Kim +7 more
doaj +2 more sources
Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron [PDF]
Cancer Management and Research, 2009 Emilio Bajetta, Sara Pusceddu, Valentina Guadalupi, Monika Ducceschi, Luigi CelioMedical Oncology Unit 2, Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, ItalyAbstract: Prevention of nausea and vomiting is the main goal of ...
Emilio Bajetta +3 more
doaj +4 more sources